Form 4 for EW Edwards Lifesciences
Accepted 2025-05-09 00:00:00 ET · period of report 2025-05-07 · accession 0001225208-25-004942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-09 | 2025-05-09 | EW | Ullem Scott B. | CFO, CVP | S - Sale+OE | $74.40 | -11.2K | 41.1K | -21% | -$837.0K |
| D | 2025-05-09 | 2025-05-09 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $45.28 | +11.2K | 52.3K | +27% | +$509.4K |
| D | 2025-05-09 | 2025-05-07 | EW | Ullem Scott B. | CFO, CVP | F - Tax | $74.92 | -1,406 | 27.7K | -5% | -$105.3K |
| D | 2025-05-09 | 2025-05-08 | EW | Ullem Scott B. | CFO, CVP | A - Grant | $0.00 | +13.4K | 41.1K | +48% | $0 |
| DM | 2025-05-09 | 2025-05-08 | EW | Ullem Scott B. | CFO, CVP | A - Grant | $0.00 | +88.6K | 75.2K | New | $0 |
| D | 2025-05-09 | 2025-05-09 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $0.00 | -11.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-09 | S | D | 11,250 | $74.40 | 41,098 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $74.12 to $74.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2025-05-09 | M | A | 11,250 | $45.28 | 52,348 | D | — | — | |
| 3 | Common | Common Stock | 2025-05-07 | F | D | 1,406 | $74.92 | 27,698 | D | — | — | |
| 4 | Common | Common Stock | 2025-05-08 | A | A | 13,400 | $0.00 | 41,098 | D | — | — | (F1) These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 5 | Derivative | Performance Rights | 2025-05-08 | A | A | 13,400 | $0.00 | 13,400 | D | — · 2028-05-08 to — | 13,400 Common Stock | (F5) Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2025-05-09 | M | D | 11,250 | $0.00 | 0 | D | $45.28 · 2019-05-17 to 2025-05-16 | 11,250 Common Stock | |
| 7 | Derivative | Employee Stock Option (Right to Acquire) | 2025-05-08 | A | A | 75,200 | $0.00 | 75,200 | D | $74.63 · 2026-05-08 to 2032-05-07 | 75,200 Common Stock | (F4) These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. |